Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Dynavax Technologies
DVAX
Dynavax Technologies
Heavy Product Reliance Will Compress Margins Yet Prompt Turnaround
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
11 May 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$11.00
1.9% undervalued
intrinsic discount
16 Aug
US$10.79
Loading
1Y
-5.8%
7D
3.0%
Author's Valuation
US$11.0
1.9% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$11.0
1.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-163m
674m
2014
2017
2020
2023
2025
2026
2028
Revenue US$430.0m
Earnings US$139.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
13.40%
Biotech revenue growth rate
13.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.00%
Calculation
US$139.09m
Earnings '28
x
9.11x
PE Ratio '28
=
US$1.27b
Market Cap '28
US$1.27b
Market Cap '28
/
94.32m
No. shares '28
=
US$13.43
Share Price '28
US$13.43
Share Price '28
Discounted to 2025 @ 7.00% p.a.
=
US$10.96
Fair Value '25
